Tocilizumab treatment in patients with Schnitzler syndrome: An open-label proof-of-concept study

被引：0
|
作者：
Bonnekoh, H. [1 ]
Frischbutter, S. [1 ]
Roll, S. [2 ]
Maurer, M. [1 ]
Krause, K. [1 ]
机构：
[1] Charite Univ Med Berlin, D-10117 Berlin, Germany
[2] Charite Univ Med Berlin, Inst Social Med, D-10117 Berlin, Germany
来源：
EXPERIMENTAL DERMATOLOGY | 2021年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P041
引用
收藏
页码：E21 / E22
页数：2
相关论文
共 50 条
  • [1] Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study
    Bonnekoh, Hanna
    Frischbutter, Stefan
    Roll, Stephanie
    Maurer, Marcus
    Krause, Karoline
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (06): : 2486 - +
  • [2] Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression
    Kanes, Stephen J.
    Colquhoun, Helen
    Doherty, James
    Raines, Shane
    Hoffmann, Ethan
    Rubinow, David R.
    Meltzer-Brody, Samantha
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2017, 32 (02)
  • [3] Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study
    Unizony, Sebastian
    Matza, Mark A.
    Jarvie, Adam
    O'Dea, David
    Fernandes, Ana
    Stone, John H.
    LANCET RHEUMATOLOGY, 2023, 5 (12): : e736 - e742
  • [4] The Open-label, Proof-of-concept Study of SAGE-547 (Allopregnanolone) in the Treatment of Postpartum Depression
    Kanes, Stephen J.
    Colquhoun, Helen
    Doherty, James
    Raines, Shane
    Rubinow, David R.
    Meltzer-Brody, Samantha
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 133S - 133S
  • [5] SAFETY AND EFFICACY OF MARALIXIBAT IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: AN OPEN-LABEL PROOF-OF-CONCEPT STUDY
    Bowlus, Christopher L.
    Eksteen, Bertus
    Cheung, Angela
    Thorburn, Douglas
    Moylan, Cynthia A.
    Pockros, Paul J.
    Forman, Lisa
    Dorenbaum, Alejandro
    Hirschfield, Gideon
    Kennedy, Ciara
    Gu, Joan
    Apostol, George
    Vig, Pamela
    Levy, Cynthia
    HEPATOLOGY, 2019, 70 : 764A - 765A
  • [6] Nocturnal Asthma: Proof-of-Concept Open-Label Study with Delayed-Release Prednisone
    Alavoine L.
    Taillé C.
    Ball J.
    Knauer C.
    Witte S.
    Kent J.
    Aubier M.
    Pulmonary Therapy, 2015, 1 (1) : 43 - 52
  • [7] Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial—The RIWA study
    Andre Rodrigues Duraes
    Yasmin de Souza Lima Bitar
    Igor Santos Schonhofen
    Kethyren Santos Oliveira Travassos
    Larissa Vitória Pereira
    Jose Admirço Lima Filho
    Mansueto Gomes Neto
    Roque Aras Junior
    Leonardo Roever
    American Journal of Cardiovascular Drugs, 2021, 21 : 363 - 371
  • [8] Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study
    Jang, Jun Ho
    Wong, Lily
    Ko, Bor-Sheng
    Yoon, Sung-Soo
    Li, Katie
    Baltcheva, Irina
    Nidamarthy, Prasanna Kumar
    Chawla, Raghav
    Junge, Guido
    Yap, Eng Soo
    BLOOD ADVANCES, 2022, 6 (15) : 4450 - 4460
  • [9] Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
    Poddubnyy, Denis
    Hermann, Kay-Geert A.
    Callhoff, Johanna
    Listing, Joachim
    Sieper, Joachim
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (05) : 817 - 823
  • [10] Ustekinumab For The Treatment Of Patients With Active Ankylosing Spondylitis: Results Of a 28-Week, Prospective, Open-Label, Proof-Of-Concept Study (TOPAS)
    Poddubnyy, Denis
    Callhoff, Johanna
    Listing, Joachim
    Sieper, Joachim
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S766 - S766
12345